Search
Gadobenic acid
go.drugbank.com/drugs/DB00743ApprovedInvestigational[A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.
Lanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection.
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedHydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised ...
Selegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedA selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may...
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Sulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.[L43942]
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnA216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the US
Flurothyl
go.drugbank.com/drugs/DB08969ApprovedWithdrawnIt was formerly used to induce convulsions as a alternative to electroshock therapy.
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.